1. Wild-type K-RAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado RG;J Clin Oncol,2008
2. Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer. Hold back, we are not there yet;Baselga J;J Clin Oncol,2007
3. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies;Benvenuti S;Cancer Res,2007
4. 5. Berlin J, Malik I, Picus J, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leukovorin (IFL) in metastatic colorectal patients. Proc Eur Soc Med Oncol Abstract #265PD, 2004